Clinical trials recruiting for KRAS G12C Mutation
Fewer than 3 recruiting trials found.
Phase breakdown
Drugs and treatments being studied
| Intervention | Trials |
|---|---|
| Cetuximab | 1 |
| KQB198 | 1 |
| KQB365 | 1 |
| fulzerasib | 1 |
Where trials are recruiting (top US states)
| State | Recruiting trials |
|---|---|
| Arizona | 1 |
| Colorado | 1 |
| Florida | 1 |
| Massachusetts | 1 |
| Michigan | 1 |
| Minnesota | 1 |
| Ohio | 1 |
| Oklahoma | 1 |
| Pennsylvania | 1 |
| Texas | 1 |
| Virginia | 1 |
Top cities
Self-screener
Recruiting trials
- A Study to Investigate the Safety and Efficacy of KQB365 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies
- Fulzerasib Sequential Sintilimab Plus Platinum-Doublet Neoadjuvant Therapy for Resectable KRAS G12C-Mutant NSCLC
Related conditions
Trials recruiting for KRAS G12C Mutation often also study these conditions. Each links to its own recruiting-trial list.
Common questions
Are these trials free to join?
Study-related care in a clinical trial is usually provided at no cost to participants, and some trials reimburse travel. Costs vary by study - the trial team will explain what is and is not covered. Confirm this directly with them.
How do I know if I am eligible for KRAS G12C Mutation trials?
Each trial lists inclusion and exclusion criteria. The screener above checks stated age and sex only. The full eligibility (your medical history, current medications, test results) is assessed by the study team. Open any trial to read its criteria, then contact the site.
Is this list complete?
No. For the full list, search ClinicalTrials.gov.